Constantine S. Mitsiades

Constantine S. Mitsiades's AcademicInfluence.com Rankings

Philosophy

#7824

World Rank

#11086

Historical Rank

Logic

#4857

World Rank

#6189

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Constantine S. Mitsiades Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Constantine S. Mitsiades's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc (2011) (2474)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins (2014) (1044)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets (2007) (885)
NF-κB as a Therapeutic Target in Multiple Myeloma* (2002) (854)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. (2010) (813)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. (2002) (801)
Molecular sequelae of proteasome inhibition in human multiple myeloma cells (2002) (769)
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. (2003) (730)
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. (2002) (670)
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. (2005) (661)
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. (2004) (652)
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor (2014) (646)
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. (2003) (589)
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. (2004) (570)
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy (2011) (521)
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. (2006) (511)
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. (2002) (493)
Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications (2002) (491)
NF-kappa B as a therapeutic target in multiple myeloma. (2002) (464)
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. (2001) (440)
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. (2005) (431)
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. (2001) (421)
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. (2002) (395)
The role of tumour–stromal interactions in modifying drug response: challenges and opportunities (2013) (381)
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. (2006) (360)
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. (2009) (347)
Antimyeloma activity of heat shock protein-90 inhibition. (2005) (327)
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia (2009) (321)
Molecular sequelae of histone deacetylase inhibition in human malignant B cells. (2003) (309)
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity (2010) (291)
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. (2004) (279)
Bortezomib: proteasome inhibition as an effective anticancer therapy. (2005) (274)
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. (2009) (259)
The Akt pathway: molecular targets for anti-cancer drug development. (2004) (246)
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. (2003) (244)
JNK-dependent Release of Mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) Cells* (2003) (215)
Treatment Options for Relapsed and Refractory Multiple Myeloma (2011) (213)
The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. (2006) (210)
Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. (2003) (203)
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma (2008) (202)
Suppression of Fas‐FasL‐induced endothelial cell apoptosis prevents diabetic blood‐retinal barrier breakdown in a model of streptozotocin‐induced diabetes (2003) (196)
Cytokines modulate telomerase activity in a human multiple myeloma cell line. (2002) (189)
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma (2008) (186)
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. (2004) (185)
Nuclear Factor-κB p65 Mediates Tumor Necrosis Factor α-induced Nuclear Translocation of Telomerase Reverse Transcriptase Protein (2003) (180)
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. (2014) (180)
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma (2003) (177)
Focus on multiple myeloma. (2004) (175)
Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. (2014) (170)
New drugs for myeloma. (2007) (170)
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. (2009) (164)
Proteasome inhibitor therapy in multiple myeloma (2005) (163)
Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. (2003) (157)
Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. (2012) (156)
Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. (2002) (155)
An epigenomic approach to therapy for tamoxifen-resistant breast cancer (2014) (155)
The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. (1998) (155)
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). (2004) (153)
Identification of genes modulated in multiple myeloma using genetically identical twin samples. (2004) (151)
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. (2011) (150)
Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. (2012) (147)
Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. (2004) (146)
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. (2009) (143)
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. (2007) (143)
CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications (2002) (139)
Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. (2001) (138)
Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers (2011) (131)
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. (2004) (131)
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. (2004) (130)
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. (2007) (127)
Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. (2007) (125)
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. (2004) (123)
Bortezomib: proteasome inhibition as an effective anticancer therapy. (2006) (122)
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. (2006) (120)
Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. (2003) (118)
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. (2012) (117)
MLN120B, a Novel IκB Kinase β Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo (2006) (114)
CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. (2003) (113)
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells (2007) (112)
Proteasome Inhibition in the Treatment of Cancer (2005) (111)
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. (2003) (110)
Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. (2003) (109)
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. (2005) (108)
GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex (2014) (101)
Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo (2008) (100)
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies (2005) (98)
Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid Cancer (2005) (93)
Bortezomib in the front-line treatment of multiple myeloma (2008) (91)
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. (2008) (90)
The role of Fas and FasL as mediators of anticancer chemotherapy. (2001) (89)
Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment (2007) (88)
Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells (2007) (87)
Inhibition of Hsp90 attenuates inflammation in endotoxin‐induced uveitis (2007) (86)
Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease (2007) (86)
Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. (2011) (84)
Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. (2003) (81)
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. (2004) (81)
Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study (2008) (77)
The emerging role of novel therapies for the treatment of relapsed myeloma. (2007) (77)
New Proteasome Inhibitors in Myeloma (2012) (76)
Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib (2009) (76)
The use of novel agents in the treatment of relapsed and refractory multiple myeloma (2009) (75)
Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. (2002) (75)
An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. (2021) (74)
Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose‐escalation study (2010) (74)
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors (2012) (74)
Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton. (2003) (73)
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. (2003) (73)
The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma (2017) (73)
Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma (2011) (71)
A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. (2001) (70)
Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells (2008) (70)
Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence. (2021) (69)
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias (2013) (68)
Proteasome inhibition in hematologic malignancies (2004) (68)
Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. (2006) (67)
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide–bortezomib combinations (2015) (65)
Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial. (2006) (65)
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma (2009) (64)
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. (2009) (64)
Heat Shock Protein 90 Is Critical for Regulation of Phenotype and Functional Activity of Human T Lymphocytes and NK Cells (2013) (63)
Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma (2014) (62)
Targeting BRAFV600E in thyroid carcinoma: therapeutic implications (2007) (62)
Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells (2003) (61)
Fas Signaling in Thyroid Carcinomas Is Diverted from Apoptosis to Proliferation (2006) (61)
Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ (2012) (61)
Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma (2010) (61)
Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases (2001) (59)
Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. (2013) (58)
Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation (2014) (58)
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341 (2004) (56)
Novel biological therapies for the treatment of multiple myeloma. (2005) (54)
Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer (2001) (53)
Molecular staging by RT-PCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer (2004) (53)
Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance (2013) (52)
The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer. (2003) (52)
Combination of Somatostatin Analog, Dexamethasone, and Standard Androgen Ablation Therapy in Stage D3 Prostate Cancer Patients with Bone Metastases (2004) (50)
From the bench to the bedside: emerging new treatments in multiple myeloma (2007) (49)
Novel biologically based therapies for Waldenstrom's macroglobulinemia. (2003) (48)
A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. (2010) (48)
Proteasome inhibition as a new therapeutic principle in hematological malignancies. (2006) (47)
The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells (2015) (47)
Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma (2012) (47)
Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies (2014) (47)
Phenotypic and Functional Effects of Heat Shock Protein 90 Inhibition on Dendritic Cell (2007) (47)
Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias (2009) (47)
Role of alpha 4 integrin (CD49d) in the pathogenesis of diabetic retinopathy. (2009) (46)
Novel therapies in the treatment of multiple myeloma. (2009) (45)
Constitutive nuclear factor-kappaB activity is crucial for human retinoblastoma cell viability. (2002) (44)
CC-5013 (Celgene). (2004) (42)
Skin Manifestations of Cushing Disease in Children and Adolescents Before and After the Resolution of Hypercortisolemia (1998) (42)
Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. (2009) (42)
Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells (2013) (42)
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial (2010) (40)
A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM). (2006) (40)
Insulin-like Growth Factor-1- and Interleukin-6-related Gene Variation and Risk of Multiple Myeloma (2009) (40)
Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. (2009) (39)
Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias (2001) (39)
Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. (2010) (39)
The treatment of relapsed and refractory multiple myeloma. (2007) (39)
Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling (2005) (38)
NF-κB dysregulation in multiple myeloma. (2016) (38)
Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing. (2005) (38)
A Phase 1 Trial of Lenalidomide (REVLIMID®) with Bortezomib (VELCADE®) in Relapsed and Refractory Multiple Myeloma. (2005) (38)
Management of myeloma-associated renal dysfunction in the era of novel therapies (2012) (37)
Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer. (2006) (37)
The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro. (2007) (37)
Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of b1-integrin and phosphatidylinositol 3-kinase/AKT signaling beta. (2003) (36)
H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia. (2012) (36)
Lenalidomide in multiple myeloma (2006) (35)
Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma (2006) (35)
A novel panel of protein biomarkers for predicting response to thalidomide‐based therapy in newly diagnosed multiple myeloma patients (2011) (35)
Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study. (2007) (34)
β-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells (2002) (33)
Inhibition of tumor cells interacting with stromal cells by xanthones isolated from a Costa Rican Penicillium sp. (2012) (33)
Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. (2005) (33)
Safety and Activity of KOS-953 in Patients with Relapsed Refractory Multiple Myeloma (MM): Interim Results of a Phase 1 Trial. (2005) (32)
2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27 (2004) (32)
Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. (2012) (32)
Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions (2018) (32)
Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study. (2007) (31)
Lenalidomide for the treatment of relapsed and refractory multiple myeloma (2012) (31)
Future agents and treatment directions in multiple myeloma (2014) (30)
Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up (2010) (30)
Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations. (2003) (30)
Microenvironmental Influence on Pre-Clinical Activity of Polo-Like Kinase Inhibition in Multiple Myeloma: Implications for Clinical Translation (2011) (30)
Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents (2012) (30)
Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (2014) (29)
Autophagy suppresses Ras-driven epithelial tumourigenesis by limiting the accumulation of reactive oxygen species (2017) (29)
Tanespimycin as antitumor therapy. (2011) (29)
In vitro anti‐myeloma activity of the Aurora kinase inhibitor VE‐465 (2009) (29)
Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease (2014) (29)
The power of proteasome inhibition in multiple myeloma (2018) (28)
Novel therapies in myeloma (2007) (28)
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia (2009) (28)
Proteasome inhibitors as therapeutics. (2005) (28)
Mouse models of human myeloma. (2007) (28)
Autologous stem cell transplantation and multiple myeloma cancer stem cells. (2012) (28)
Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment (2017) (27)
A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma (2011) (26)
Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition. (2007) (26)
A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (2008) (25)
Male breast adenocarcinoma in a prostate cancer patient following prolonged anti-androgen monotherapy. (2004) (25)
Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug (2001) (25)
From the bench to the bedside: emerging new treatments in multiple myeloma. (2007) (25)
Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. (2021) (25)
Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (2014) (25)
Genome-scale screens identify factors regulating tumor cell responses to natural killer cells (2021) (25)
Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma (2011) (24)
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression (2021) (24)
Molecular and cellular effects of multi‐targeted cyclin‐dependent kinase inhibition in myeloma: biological and clinical implications (2011) (24)
Phenothiazines induce PP 2 A-mediated apoptosis in T cell acute lymphoblastic leukemia (2014) (23)
Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells (2012) (23)
An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors. (2018) (23)
The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer (2019) (23)
Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings (2011) (22)
Three-dimensional type I collagen co-culture systems for the study of cell-cell interactions and treatment response in bone metastases. (2000) (22)
Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma (2019) (22)
Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study (2013) (22)
The Cyclophilin A-CD147 complex promotes bone marrow colonization of B-cell malignancies: implications for therapy (2015) (22)
Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution (2016) (21)
Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma. (2007) (21)
Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma (2017) (20)
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy (2009) (19)
Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer (2002) (19)
Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. (2010) (18)
ligand-induced apoptosis in human multiple myeloma cells Intracellular regulation of tumor necrosis factor-related apoptosis-inducing (2002) (18)
Management of relapsed and relapsed/refractory multiple myeloma. (2011) (18)
Novel therapeutic avenues in myeloma: changing the treatment paradigm. (2007) (17)
Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias. (2003) (17)
Proteasome inhibition as a therapeutic strategy for hematologic malignancies (2005) (16)
Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R (2014) (16)
Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications. (2009) (15)
Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway. (2015) (15)
Combined Vorinostat, Lenalidomide and Dexamethasone Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase I Study. (2009) (15)
Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma. (2013) (15)
Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening (2008) (14)
Conversion of nested reverse-transcriptase polymerase chain reaction from positive to negative status at peripheral blood during androgen ablation therapy is associated with long progression-free survival in stage D2 prostate cancer patients. (2001) (14)
Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice. (2020) (14)
How "immunomodulatory" are IMIDs? (2011) (14)
Erratum: Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma (Leukemia (2008) vol. 22 (1925-1932) 10.1038/leu.2008.174) (2008) (13)
Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets. (2013) (12)
Dideoxyfingerprinting (ddF) analysis of the type X collagen gene (COL10A1) and identification of a novel mutation (S671P) in a kindred with Schmid metaphyseal chondrodysplasia. (1996) (12)
The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib (2012) (11)
Emerging drugs in multiple myeloma (2007) (11)
High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study. (2009) (11)
RANDOMISED CONTROLLED CLINICAL TRIAL OF A COMBINATION OF SOMATOSTATIN ANALOG AND DEXAMETHASONE PLUS ZOLEDRONATE VS. ZOLEDRONATE IN PATIENTS WITH ANDROGEN ABLATION REFRACTORY PROSTATE CANCER (2006) (11)
M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models (2021) (11)
Dasatinib (BMS-354825): A Multi-Targeted Kinase Inhibitor with Activity Against Multiple Myeloma. (2005) (10)
The mTOR Inhibitor RAD001 (everolimus) Is Active Against Multiple Myeloma Cells In Vitro and in Vivo. (2004) (10)
A genome-wide Drosophila epithelial tumorigenesis screen identifies Tetraspanin 29Fb as an evolutionarily conserved suppressor of Ras-driven cancer (2018) (10)
MAP3K8 kinase regulates myeloma growth by cell‐autonomous and non‐autonomous mechanisms involving myeloma‐associated monocytes/macrophages (2013) (10)
Activity of New Heat Shock Protein 90 (hsp90) Inhibitor NVP-AUY922 Against Myeloma Cells Sensitive and Resistant to Conventional Agents. (2007) (10)
Management of Relapsed and Relapsed/Refractory Multiple Myeloma (2011) (10)
A T cell-binding fragment of fibrinogen can prevent autoimmunity. (2010) (10)
CD 40 induces human multiple myeloma cell migration via phosphatidylinositol 3 – kinase / AKT / NF-B signaling (2003) (10)
Combination of the mTOR inhibitor Rapamycin and Revlimid ( CC-5013 ) has synergistic activity in Multiple Myeloma (2004) (10)
CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. (2005) (10)
Defibrotide (DF) Targets Tumor-Microenvironmental Interactions and Sensitizes Multiple Myeloma and Solid Tumor Cells to Cytotoxic Chemotherapeutics. (2004) (10)
Comprehensive Molecular Characterization of Malignant and Microenvironmental Cells in Waldenstrom’s Macroglobulinemia by Gene Expression Profiling. (2007) (10)
A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population (2010) (10)
Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines. (2003) (9)
Bortezomib in the management of multiple myeloma (2009) (9)
Proteasome inhibitors as therapeutics: Figure 1 (2005) (9)
Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: A phase I study. (2016) (9)
Role of 4 Integrin ( CD 49 d ) in the Pathogenesis of Diabetic Retinopathy (2009) (9)
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms* (2012) (9)
Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of 1-Integrin and Phosphatidylinositol 3-Kinase / AKT Signaling 1 (2003) (9)
Dose escalating trial of 17-AAG with bortezomib (BZ) in patients with relapsed refractory multiple myeloma (MM) (2005) (9)
IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity. (2004) (9)
A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice (2013) (8)
LAQ824 is a novel histone deacetylase inhibitor with significant activity against multiple myeloma: Results of a pre-clinical evaluation in vitro and in vivo. (2002) (8)
Epigenetic modulation in hematologic malignancies: challenges and progress. (2009) (8)
Management of relapsed and relapsed refractory myeloma. (2007) (8)
Cancer and bone repair mechanism: clinical applications for hormone refractory prostate cancer. (2000) (8)
High-throughput approaches to discover novel immunomodulatory agents for cancer (2012) (8)
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma (2021) (7)
Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (2008) (7)
Emerging trends in the clinical use of bortezomib in multiple myeloma. (2005) (7)
Phase I Clinical Trial of Oral Administration of the Histone Deacetylase (HDAC) Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed/Refractory Multiple Myeloma (MM). (2004) (7)
Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM). (2010) (7)
Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment (2020) (7)
Anti-Tumor Activity of KOS-953, a Cremophor-Based Formulation of the hsp90 Inhibitor 17-AAG. (2004) (7)
A biphenyl inhibitor of eIF4E targeting an internal binding site enables the design of cell-permeable PROTAC-degraders. (2021) (6)
Phase 1 trial of 17-AAG in patients with relapsed and refractory multiple myeloma (MM) (2005) (6)
Anti-Tumor Activity of IPI-504, a Novel Hsp90 Inhibitor in Multiple Myeloma. (2004) (6)
An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma (2014) (6)
Does maintenance therapy with thalidomide benefit patients with multiple myeloma? (2007) (6)
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma (2008) (6)
Targeting Bcl-2 as Therapy for Multiple Myeloma. (2005) (6)
Bortezomib-Associated Peripheral Neuropathy: Relationship Between Clinical Neurophysiologic Evidence in Previously Untreated Multiple Myeloma Patients and Preclinical Characterization in a Mouse Model. (2009) (6)
Bortezomib Induces Proliferation of Mesenchymal Progenitor Cells and Promotes Differentiation towards Osteoblastic Lineage. (2006) (6)
A proto-oncogene BCL 6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells (2010) (5)
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1 (2022) (5)
Comprehensive Genome-Wide Profile of Regional Gains and Losses in Multiple Myeloma Using Array-CGH: The 1q21 Amplification and Potential Role of the BCL-9 Gene in Multiple Myeloma Pathogenesis. (2004) (5)
A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies. (2004) (5)
Defibrotide (DF), an Orally Bioavailable Modulator of Myeloma Tumor-Microenvironment Interactions: Molecular Sequelae and Clinical Implications. (2006) (5)
Erratum: Autophagy suppresses Ras-driven epithelial tumourigenesis by limiting the accumulation of reactive oxygen species (2017) (5)
The Combination of the mTOR Inhibitor Rapamycin and Proteasome Inhibitor Bortezomib Is Synergistic In Vitro in Multiple Myeloma. (2006) (5)
Can thalidomide improve outcome in patients with multiple myeloma? (2006) (4)
MLN4924, a Novel Investigational NEDD8 Activating Enzyme Inhibitor, Exhibits Preclinical Activity In Multiple Myeloma and Waldenström's Macroglobulinemia through Mechanism Distinct From Existing Proteasome Inhibitors (2010) (4)
P2X7 polymorphism and chronic lymphocytic leukaemia (2003) (4)
Defibrotide Counteracts the Modifications of Anti-Thrombotic Phenotype of Endothelial Cells Induced by Thalidomide. (2007) (4)
The Proteasome Inhibitor NPI-0052 in Combination with Bortezomib Induces Antitumor Activity in Waldenstrom Macroglobulinemia. (2006) (4)
A241 Vorinostat/Lenalidomide/Dexamethasone: A Phase I Study (2009) (4)
The Treatment of Multiple Myeloma Patients Not Eligible for Asct (2010) (4)
Genome-Scale Crispr-Cas9 Knockout Studies Reveal Mutifactorial and Functionally Overlapping Mechanisms of Myeloma Cell Resistance to Proteasome Inhibition (2014) (4)
Anti-Myeloma Activity of Selective PI-3K/PDK/mTOR Inhibitor BEZ235. (2007) (3)
Receptor activator of nuclear factor-kappa B (RANK) ligand expression: In human multiple myeloma cells. (2001) (3)
A Multi-Center Phase I/II Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Avanced Multiple Myeloma Patients. (2006) (3)
Avicins: A Novel Class of Anti-Myeloma Agents. (2004) (3)
The Antidiabetic Biguanide Metformin Induces Growth Arrest in Multiple Myeloma Cells in Vitro, overcoming the Effect of Stromal Cells (2008) (3)
The Interaction of Bortezomib with P-Gp, MRP-1 and BCRP Drug Transporters: Implications for Therapeutic Applications of Bortezomib in Advanced Multiple Myeloma and Other Neoplasias. (2009) (3)
Pre-clinical evidence for an anti-tumor activity of defibrotide, a DNA-based, endothelium stabilizing drug (2007) (3)
BET Bromodomain Degradation As a Therapeutic Strategy in Multiple Myeloma (2016) (3)
Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma (2019) (2)
PKC412 Is a Multi-Targeting Kinase Inhibitor with Activity Against Multiple Myeloma In Vitro and In Vivo. (2005) (2)
Activity of CDK1/2 Inhibitor LCQ195 Against Multiple Myeloma Cells. (2007) (2)
CRISPR Screens Identify Mechanisms of Natural Killer Cell Evasion across Blood Cancers (2019) (2)
CRISPR Screens Identify Mechanisms of Natural Killer Cell Evasion across Blood Cancers (2019) (2)
Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma (2010) (2)
Compartment-Specific Bioluminescence Imaging (CS-BLI): A High-Throughput Approach To Identify Novel Anti-Neoplastic Therapies That Overcome the Protection of Stromal Cells. (2007) (2)
Therapeutic Discovery Adenosine A 2 A and Beta-2 Adrenergic Receptor Agonists : Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening (2012) (2)
Serum Protein Profiling with Mass Spectrometry for the Diagnosis of Myelodysplastic Syndromes. (2004) (2)
Lenalidomide and Bortezomib: Targeting Osteoclastogenesis, Osteoclast Survival Factors, and Bone Remodeling Markers in Multiple Myeloma. (2007) (2)
JS-K, a GST-Activated Nitric Oxide Generator, Induces DNA-Double Strand Breaks and Inhibits Growth and Survival of Multiple Myeloma Cells In Vitro and In Vivo. (2006) (2)
Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma (2013) (2)
MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. (2011) (2)
Heat shock protein-27 confers drug-resistance in multiple myeloma cells. (2002) (2)
Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma (2008) (2)
Anti-Myeloma Activity of the Small-Molecule Aurora Kinase Inhibitor VE465. (2006) (2)
Functional Genomic Landscape of Genes with Recurrent Mutations in Multiple Myeloma (2018) (2)
Compartment-Specific Bioluminescence Imaging (CS-BLI) High- Throughput Assays Provide Comparative Insights into the Impact of Osteoclasts Vs. Stromal Cells on Activity of Anti-Myeloma Therapeutics (2008) (2)
Hedgehog Pathway as a Potential Therapeutic Target in Multiple Myeloma. (2007) (2)
Abstract C225: IL1RAP as functionally relevant target for stem-cell directed therapy in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). (2013) (2)
Emerging treatments of multiple myeloma; beyond IMIDs and bortezomib (2009) (2)
Anti-Myeloma Activity of the Dual Akt/p70 S6K Inhibitor EXEL-6075. (2007) (2)
Cells : Clinical Implications Antibody , Induces Cytotoxicity in Human Multiple Myeloma Mechanisms by which SGN-40 , a Humanized Anti-CD 40 (2004) (2)
Antimyeloma Efficacy of Plitidepsin (Aplidin®): From Bench to the Bedside. (2007) (2)
B257 Vorinostat in Combination with Other Anti-MM Agents (2009) (2)
Pharmacological Perturbation of the Immunoproteasome in Hematologic Neoplasias: Therapeutic Implications (2019) (2)
A224 Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma (2009) (2)
Activity of the NEDD8-specific inhibitor MLN 4924 in multiple myeloma and Waldenström's macroglobulinemia, and effect on miRNA expression. (2010) (1)
Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052. (2005) (1)
Proteomics as a Functional Tool in Evaluating Bortezomib Treatment and Drug Resistance Mechanism. (2009) (1)
Interactions of the Mdm2/p53 and Proteasome Pathways: Implications for Combination Strategies to Enhance the Anti-Myeloma Activity of Bortezomib (2008) (1)
Novel Combination Therapies for the Treatment of Relapsed/Refractory Multiple Myeloma: Current Phase I/II Combinations (2009) (1)
A Phase I/II Trial on Melphalan, Prednisone, Thalidomide and Defribotide Combination in Relapsed/Refractory Multiple Myeloma Patients. (2007) (1)
Network signatures based on gene pair expression ratios improve classification and the analysis of muscle-invasive urothelial cancer (2015) (1)
Pharmacogenomics Study of Biological Pathways Related to Bortezomib Activity in Myeloma. (2007) (1)
Defining Primary Marrow Microenvironment-Induced Synthetic Lethality and Resistance for 2,684 Approved Drugs Across Molecularly Distinct Forms of Multiple Myeloma (2015) (1)
POU2AF1 As a Master Regulator of Oncogenic Transcription Factor Networks in Myeloma (2020) (1)
CRISPR Activation Screen for HDAC Inhibitor Resistance (2018) (1)
Atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo. (2004) (1)
IGF-II is a major proliferative/anti-apoptotic cytokine and a therapeutic target in multiple myeloma, other hematologic neoplasias and solid tumors. (2004) (1)
POU2AF1 As a Master Regulator of Oncogenic Transcription Factor Networks in Myeloma (2020) (1)
CRISPR Activation Screen for HDAC Inhibitor Resistance (2018) (1)
Maximizing the clinical benefit of novel therapies in multiple myeloma. (2009) (1)
1 JSK , a GST-activated nitric oxide generator , induces DNA double strand breaks , activates DNA damage response pathways , and induces apoptosis in vitro and in vivo in human multiple myeloma cells (2007) (1)
TIMP3 Inhibits Vascular Leakage and Leukostasis in an Animal Model of Streptozotocin-Induced Diabetes (2007) (1)
Initial Treatment of Multiple Myeloma in Transplant-Eligible Patients (2010) (1)
Faculty Opinions recommendation of Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. (2009) (1)
Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor – Microenvironment Interactions. (2010) (1)
Abstract PR12: Biological insights into tumor-bone marrow microenvironment interactions derived from a humanized murine model (2015) (1)
Reversine: A Chemical Probe Providing Insight into Myeloma Biology and Potential Therapeutic Applications. (2006) (1)
Targeting Cyclin D1 in the Treatment of Multiple Myeloma: Preclinical Validation of a Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00. (2006) (1)
Pre-Clinical Activity of the Novel, First-in-Class p97 Inhibitor, CB-5083, in Multiple Myeloma (2014) (1)
Characterization of Lineage Vs. Context-Dependent Essential Genes in Multiple Myeloma Using Crispr/Cas9 Genome Editing (2016) (1)
Myeloma Patient-Derived Mesenchymal Stem Cells Grown In 3-D Culture Induce Primary Myeloma Cell Proliferation and Resistance To Therapy (2013) (1)
Gene expression analysis of tumor cells sensitive and resistant to PS-341 (Bortezomib) treatment: Clinical implications. (2003) (1)
Inference and Analysis of Gene Regulatory Networks in R (2016) (1)
Tight Junction Protein 1: New Insights into Proteasome Inhibitor Resistance and Myeloma Pathophysiology. (2016) (1)
NVP-AEW541: A Selective Small Molecule IGF-1R Tyrosine Kinase Inhibitor Is Active Against Multiple Myeloma and Other Hematologic Neoplasias and Solid Tumors. (2004) (1)
The research mission in myeloma (2009) (1)
Molecular markers of MM cell sensitivity and resistance to Natural Killer cells: implications for anti-MM immunotherapy (2019) (1)
PKC412 Effectively Inhibits Constitutively Activated FGFR3 Mutants in Murine Leukemia Models and t(4;14) Myeloma Cell Lines. (2004) (1)
The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in Preclinical Studies. (2009) (1)
Pharmacogenomics (PGx) Research in the APEX Randomized Multicenter International Phase 3 Trial Comparing Bortezomib and High-Dose Dexamethasone (Dex). (2005) (1)
Abstract 4713: BET bromodomain degradation as a therapeutic strategy in drug-resistant multiple myeloma (2016) (1)
Nanoparticle Arsenic Compound Realgar Effectively Targets Myeloma Stem-Like Side Population (2013) (1)
Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM). (2009) (1)
Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications. (2009) (1)
Integrated Evaluation of Results from Genome-Wide Association Studies and Crispr/Cas9-Based Functional Genomics in Myeloma: Implications for Cell-Autonomous Vs. Non-Autonomous Role of Candidate Genes in Myeloma Pathophysiology (2016) (0)
Genome-scale CRISPR-Cas9 knockout studies to characterize the mechanisms of myeloma cell treatment resistance. (2015) (0)
Aplidine for treatment of multiple myeloma (2004) (0)
Anti–FasL Neutralizing Antibody Increases the Efficacy of PDT and Reduces the Apoptotic Damage in a Rat Laser Model (2005) (0)
Combinatorial CRISPR-knockout identifies interactions between key genes and regulatory pathways in myeloma (2019) (0)
Effects of Tanespimycin On Glucocorticoid Receptor Translocation. (2009) (0)
Monitoring Cytotoxic Effects In Non‐Cancerous Cells via Docetaxel (2018) (0)
Functional Mapping of Multiple Myeloma Kinome Using a Small Molecule Inhibitor Library (2014) (0)
Cell Non-Autonomous Modulation Of Tumor Cell Responses To Pharmacological Inhibition Of The Proteasome (2013) (0)
Synergistic Activity of Adenosine A2A and Beta-2 Adrenergic Receptor Agonists in Myeloma Cells in the Context of Tumor-Stromal Interactions (2008) (0)
Functional Genomic Landscape of Natural Killer Cell Evasion in Multiple Myeloma (2021) (0)
Compartment-Specific Bioluminescence Imaging Platform for the Open-Ended Identification of Novel Immunomodulatory Agents and High-Throughput Evaluation of Anti-Tumor Immune Function (2010) (0)
GRN163L, a Novel and Potent Telomerase Inhibitor, Inhibits Myeloma Cell Growth In Vitro and In Vivo . (2005) (0)
In Vitro Anti-Myeloma Activity of the Multitargeted Kinase Inhibitor Midostaurin in the Context of Heterotypic Cocultures of Myeloma Cells with Nonmalignant Microenvironmental Accessory Cells (2011) (0)
Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment. (2004) (0)
Abstract 2834: Genomewide CRISPR studies of sequential treatment with CRBN-based degronimids: Insights into the molecular evolution of treatment resistance in myeloma and beyond (2018) (0)
Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML (2012) (0)
Single-cell functional genomics of natural killer cell evasion in blood cancers (2022) (0)
O-20 Noninvasive detection ofmyelodysplastic syndromes using serum proteome profiling (2005) (0)
Compositions for treating cancer using the proteasome inhibitor PS-341 (2003) (0)
The Survivin Suppressant YM155 Overcomes Microenvironment-Mediated Immune Resistance In a Humanized Multiple Myeloma Mouse Model (2013) (0)
Molecular Pathways Induced by Tumor–Microenvironment Interactions in Myeloma and the Regulatory Role of Heat-Shock Proteins (2009) (0)
Time to Development of Treatment-Emergent Extramedullary and Osseous Plasmacytomas in the Era of Novel Agents: An Analysis of Upfront Regimens in Newly Diagnosed MM Incorporating Lenalidomide and Bortezomib (2014) (0)
Abstract LB-118: Characterization of lineage vs. context-dependent essential genes in multiple myeloma using CRISPR-Cas9 genome editing (2017) (0)
Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing (2011) (0)
Abstract GS1-07: Treatment persistence of residual breast tumors through an embryonic diapause-like cancer cell state with suppressed myc activity (2021) (0)
Abstract 6374: BMP6 overcomes multiple myeloma-induced bone disease by inducing the expression of small leucine-rich proteoglycans (2022) (0)
1 receptor inhibitors of insulin growth factor type to inhibit tumor cell growth. (2005) (0)
In Vitro and In Vivo Anti-Myeloma Activity of PRLX, an Orally-Bioavailable Agent Against Cells with Constitutive Activation of Ras or Its Downstream Pathway. (2007) (0)
The Proteasome Inhibitor Bortezomib (Velcade, PS–341) Induces Apoptosis in Human Retinoblastoma Cells: Therapeutic Implications (2006) (0)
Gain-of-function studies with CRISPR-based transcriptional activation at endogenous genomic loci reveals genes with critical roles for myeloma cells (2019) (0)
Histone Deacetylase-6 (HDAC6) Modulates Akt and STAT3 Activity Via Heat Shock Protein (Hsp) 90 in Human Multiple Myeloma (MM) Cells. (2006) (0)
High-Resolution Assessment of Gains and Losses of Chromosomes in Patients with Multiple Myeloma Treated with Bortezomib. (2007) (0)
CRISPR Activation Screen for Drivers of MM Cell Proliferation (2018) (0)
Heterogeneity of Molecular Mechanisms Determining Blood Cancer Cell Lines Resistance to Natural Killer Cells in the Context of Tumor-Stromal Interactions: Insights from Studies of Pooled "DNA-Barcoded" Cell Line Panels (2019) (0)
CRISPR-based functional genomics landscape of genes recurrently mutated in MM (2019) (0)
Microenvironment-Dependent Synthetic Lethality: Implications for Tumor Pathophysiology and Anti-Cancer Drug Discovery. (2009) (0)
H2.0-Like Homeobox (HLX) Induces Unlimited Clonogenicity, Blocks Differentiation, and Cooperates with FLT3-ITD in the Induction of Acute Myeloid Leukemia (2012) (0)
Identification of Molecular Markers of Tumor Cell Sensitivity and Resistance to Natural Killer Cells through Genome-Wide CRISPR Activation and CRISPR Editing Screens in Multiple Myeloma Cell Lines: Implications for Anti-Myeloma Immunotherapy (2018) (0)
Functional Characterization of Genes Driving Enhanced Biological Aggressiveness of Myeloma Cells: Identification of Novel and Understudied "Drivers" of Myeloma (2019) (0)
Synergistic Enhancement of Conventional Anti-MM Drugs Efficacy with Plant Isothiocyanates: Therapeutic Implications (2010) (0)
A227 Lenalidomide, Bortezomib, and Dexamethasone Is Active in High-Risk Relapsed/Refractory Myeloma (2009) (0)
Molecular markers of myeloma cell sensitivity vs. resistance to heterobifunctional degraders of oncoproteins: therapeutic implications. (2019) (0)
The Antidiabetic Biguanide Metformin Induces Growth Arrest in Retinoblastoma Cells in vitro (2009) (0)
Systematic Evaluation of Preclinical Genetically Determined Vs. Stochastic/Transient Resistance to High-Dose Melphalan Treatment in Multiple Myeloma (2015) (0)
Long-Term Interactions with Bone Marrow Stromal Cells Alter the Molecular Dependencies of Myeloma Cells: Insights from Genomewide CRISPR-Based Functional Genomic Screens (2017) (0)
P2X7 polymorphism and chronic lymphocytic leukaemia. Authors' reply (2003) (0)
Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma. (2007) (0)
Molecular Pathways That Determine the Activation State of Macrophages within the Myeloma Niche (2012) (0)
Long-Term Interactions with Bone Marrow Stromal Cells Alter the Molecular Dependencies of Myeloma Cells: Insights from Genomewide CRISPR-Based Functional Genomic Screens (2017) (0)
B350 SNS-032, a Potent and Selective CDK2, 7 and 9 Inhibitor, Demonstrates Preclinical Activity in Human Multiple Myeloma (2009) (0)
CRISPR studies identify genes preferentially essential for myeloma cells vs. other neoplasias: implications for future therapies selective against MM (2019) (0)
Activity of Plk Inhibitor BI2536 on Myeloma Cells (2008) (0)
IMW Section B (2009) (0)
Identiﬁcation of novel antigens with induced immune response in monoclonal gammopathy of undetermined signiﬁcance (2009) (0)
Mechanisms Regulating Myeloma Cell Responsiveness to Antisense Oligonucleotides Targeting IRF4 (2020) (0)
Functional Genomic Characterization of Endoplasmic Reticulum-Associated Dependencies in Multiple Myeloma - Biologic and Therapeutic Implications (2020) (0)
Pre-Clinical Analysis Of The Novel Antifolate Pralatrexate In Multiple Myeloma Reveals Functional Biomarkers Correlated With Response (2013) (0)
Activity of Human T Lymphocytes and NK Regulation of Phenotype and Functional Heat Shock Protein 90 Is Critical for (2017) (0)
Identification of specific immune responses in monoclonal gammopathy of undetermined significance with therapeutic implications (2016) (0)
Functional Genomic Characterization of Endoplasmic Reticulum-Associated Dependencies in Multiple Myeloma - Biologic and Therapeutic Implications (2020) (0)
Molecular Characterization of PS-341 (bortezomib) Resistance: Implications for Overcoming Resistance Using Lysophosphatidic Acid Acyltransferase (LPAAT)-β Inhibitors. (2004) (0)
Functional Interactions between Transcription Factors Involved in Myeloma Pathogenesis - Biological and Therapeutic Implications (2019) (0)
Antitumor Effects of the Histone Deacetylase Inhibitor Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Human Retinoblastoma Cell Lines: Therapeutic Implications (2008) (0)
Tumor Cell-Dependent Differences in Stroma-Induced Changes to Bortezomib Sensitivity. (2012) (0)
Molecular profiles of proteasome inhibition in plasma cell dyscrasias. (2004) (0)
Preclinical Development Molecular and Cellular Effects of NEDD 8-Activating Enzyme Inhibition in Myeloma (2012) (0)
Hsp90 Is Critical for the Regulation of Phenotype and Functionality of Human Dendritic Cells. (2005) (0)
Preclinical Evaluation of CRx-501, a Potent Selective A2A Agonist as a Novel Drug Candidate for the Treatment of Multiple Myeloma (2008) (0)
Abstract 5016: High-throughput patient-derived 3-dimensional organoid cultures as personalized models to assess drug response and post-treatment residual disease (2017) (0)
well tolerated in patients with relapsed multiple myeloma Immunomodulatory drug CC-5013 overcomes drug resistance and is (2013) (0)
The role of membrane raft in modulating CD40 signaling, ERK activation and cytokine production in human multiple myeloma cells. (2003) (0)
Myeloma Resistance and is Well Tolerated in Patients with Relapse Multiple Immunomodulatory Derivative of Thalidomide CC-5013 Overcomes Drug (2013) (0)
Hormones and Cancer Reviewers (2011) (0)
Proteasome inhibition as an anticancer target (2005) (0)
Insulin-like growth factor-1 receptor (IGF-1R/CD221): A target for monoclonal antibody-based therapy to overcome drug-resistance in multiple myeloma (MM), other hematologic malignancies and solid tumors (2004) (0)
Identification and Validation of Molecular Markers of Tumor Cell Resistance to Natural Killer Cells through CRISPR-Based Screens and Large-Scale Phenotypic Screens of Pooled Tumor Cell Lines (2017) (0)
MOLECULAR CANCER THERAPEUTICS | SMALL MOLECULE THERAPEUTICS M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (b5i) Delivering Efficacy in Multiple Myeloma Models (2021) (0)
Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells. (2006) (0)
AUTOSOMAL DOMINANT INHERITANCE OF SCHMID'S METAPHYSEAL CHONDRODYSPLASIA : DESCRIPTION OF A NEW FAMILY, AND INVESTIGATION OF THE COL10A1 GENE. 874 (1996) (0)
Role of ubiquitin-conjugating enzyme CDC34 in multiple myeloma. (2003) (0)
Canonical and Non Canonical Activation of Hedgehog Pathway in Multiple Myeloma (2008) (0)
Adenosine A2A Receptor Agonism and PDE Inhibition: A Synergistic Multi-Target Mechanism Discovered through Systematic Combination Screening in Multiple Myeloma (2008) (0)
Abstract P3-03-07: High-throughput pharmacogenomic platform to functionally probe breast cancer vulnerabilities in the context of the 3-dimensional tumor microenvironment (2017) (0)
Disregulated Osteogenesis By Mesenchymal Stromal Cells (MSC) After In Vivo Exposure To Multiple Myeloma: Studies In a Novel Humanized Mouse Model For Bone Remodelling In Myeloma (2013) (0)
Geldanamycin treatment reduces the inflammatory changes in the LPS–induced uveitis rat model (2004) (0)
Pomalidomide for the treatment of relapsed and refractory multiple myeloma (2014) (0)
CRISPR-Based Dual-Knockout Screens Reveals Network of Interactions between Key Dependencies for Myeloma Cells and Highlights IRF4 As a Central Regulator of Myeloma Cell Behavior (2018) (0)
314 COMBINATION OF SOMATOSTATIN ANALOG, DEXAMETHASONE, AND STANDARD ANDROGEN ABLATION THERAPY IN STAGE D3 PROSTATE CANCER PATIENTS WITH BONE METASTASES (2007) (0)
Abstract 42: Treatment-induced embryonic diapause-like adaptation through suppression of Myc activity as mediator of drug persistence in cancer (2021) (0)
Thyroid carcinoma cells and Fas-mediated apoptosis. (2005) (0)
B281 Ciliary Proteins and Hedgehog Pathway in Multiple Myeloma (2009) (0)
Interactions with a "Humanized" Mesenchymal Bone Marrow Stromal Niche In Vivo Modify the Patterns of Essential Genes for Myeloma Cells: Therapeutic Implications (2020) (0)
Delineation of Canonical and Non-Canonical NF-κB Pathways in Multiple Myeloma: Therapeutic Implications. (2007) (0)
Interactions with a "Humanized" Mesenchymal Bone Marrow Stromal Niche In Vivo Modify the Patterns of Essential Genes for Myeloma Cells: Therapeutic Implications (2020) (0)
Aberrant CDK7 Activity Drives the Cell Cycle and Transcriptional Dysregulation to Support Multiple Myeloma Growth: An Attractive Molecular Vulnerability (2021) (0)
Development of New Treatment Strategies Targeting Clonogenic and Tumorigenic Myeloma Side Population. (2010) (0)
36 Molecular events regulating solid tumor cell responses to natural killer cells (2020) (0)
Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs (2008) (0)
From cell biology to therapy: lenalidomide in relapsed/refractory multiple myeloma (2009) (0)
A342 Endothelial Stress Markers in Multiple Myeloma Patients (2009) (0)
Erratum to “A T cell-binding fragment of fibrinogen can prevent autoimmunity” [J. Autoimmun. 34 (2010) 453–459] (2011) (0)
Functional mapping of multiple myeloma kinome with library of small molecule inhibitors (2015) (0)
In Vivo Validation of Essential Genes for Myeloma Cells By CRISPR/Cas9 Studies in a Scaffold-Based System Engineered to Establish a Humanized Bone Marrow-like Microenvironment (2017) (0)
Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins (2019) (0)
Xenograft Animal Models for Preclinical Evaluation of Potential Anti-MM Therapeutics: Strengths and Limitations (2007) (0)
B Cell Transcriptional Coactivator POU2AF1 (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication (2021) (0)
Biological and Translational Considerations regarding the Recent Therapeutic Successes and Upcoming Challenges for Multiple Myeloma. (2020) (0)
therapeutic applications B blockade in multiple myeloma: κ - Biologic sequelae of nuclear factor (2013) (0)
Halofuginone, a Novel Antimyeloma Agent, Upregulates C-Jun, JNK and P-53 Protein in Vitro, and Inhibits Tumor Growth and Improves Survival in in Vivo Multiple Myeloma(MM) Animal Models (2008) (0)
Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic Index (2011) (0)
A chimeric humanized anti-CD40 antibody renders human multiple myeloma (MM) cells refractory to the mitogenic and protective effects of IL-6 (2003) (0)
Geldanamycin Treatment Reduces Choroidal Neovascularization In A Murine Model (2006) (0)
inhibitor PS-341 Molecular mechanisms mediating antimyeloma activity of proteasome (2013) (0)
Proteomic Characterization of An Isogenic Multiple Myeloma Cell Line Model of Bortezomib Resistance (2011) (0)
Addition of the Vascular Niche Component to the Human Bone Marrow-like Scaffold Model (2015) (0)
Abstract IA8: A new class of drugs active in T-ALL is revealed in a zebrafish screen (2014) (0)
How to Overcome Myeloma Stem Cell Resistance to Therapy - Targeting the Stem Cell Niche (2010) (0)
Functional Oncogenomic and Immune Response Landscape for Genes Recurrently Mutated in Myeloma (2021) (0)
1 MOLECULAR PREDICTORS OF CLINICAL RESPONSE TO THE PROTEASOME INHIBITOR BORTEZOMIB: CLINICAL IMPLICATIONS FOR INDIVIDUALIZED PATIENT-SPECIFIC ANTI-CANCER THERAPEUTIC ALGORITHMS (2005) (0)
Differential oxidative stress responses during 2-methoxyestradiol (2ME2) and dexamthasone (Dex)-induced apoptosis in multiple myeloma (MM) cells. (2002) (0)
Non-Invasive Characterization of Metabolic Drug Effects on Breast Cancer Cell Spheroids Using Two-Photon Excited Fluorescence Microscopy (2017) (0)
Effects of defibrotide on tumour adhesion and invasion in multiple myeloma, breast cancer and renal cell cancer (2008) (0)
patients with newly diagnosed multiple myeloma Lenalidomide, bortezomib, and dexamethasone combination therapy in (2012) (0)
Evaluation of the Ras/B-Raf/SHP-2 Axis in B Cell Malignancies. (2004) (0)
The Role of Heat Shock Protein 90 as a Therapeutic Target for Multiple Myeloma (2008) (0)
Accessory Cells From Diverse Tissue Microenvironments Alter Tumor Cell Responses to Multitargeted Kinase Inhibitors: Therapeutic Implications From a Large-Scale Systematic Evaluation. (2012) (0)
The Role of Bortezomib in the Treatment of Relapsed and Refractory Multiple Myeloma (2008) (0)
e- Blood Compartment-speciﬁc bioluminescence imaging platform for the high-throughput evaluation of antitumor immune function (2012) (0)
Gene Editing and Multi-Omics Reveal Novel Metabolic Vulnerabilities in t(4;14)-Associated Multiple Myeloma (2022) (0)
Continued Progress in Treatment Options for Multiple Myeloma: From Past to Present and Future (2007) (0)
Triona Ni Chonghaile Response to Cytotoxic Chemotherapy Pretreatment Mitochondrial Priming Correlates with Clinical (2011) (0)
Single-Cell Functional Genomics of Natural Killer Cell Interaction with Blood Cancers (2022) (0)
Abstract PO041: Landscape of molecular events regulating tumor cell responses to natural killer cells (2021) (0)
Use of Olfactory Receptor Genes As Controls for Genome-Scale CRISPR Functional Genomic Studies to Define Treatment Resistance Mechanisms (2020) (0)
Dual Inhibition of Canonical and Non-Canonical NF-KB Pathway Demonstrates Significant Anti-Tumor Activities in Multiple Myeloma (MM) (2011) (0)
Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma (2008) (0)
Inhibition of c-Myc Expression and Function in Hematologic Malignancies (2011) (0)
Functional Genomic and Immune Response Characterization of PTEN Loss: Therapeutic Implications for Myeloma (2021) (0)
Use of Olfactory Receptor Genes As Controls for Genome-Scale CRISPR Functional Genomic Studies to Define Treatment Resistance Mechanisms (2020) (0)
malignant B cells Molecular sequelae of histone deacetylase inhibition in human (2013) (0)
Co-Culture of Myeloma and Endothelial Cells: Defibrotide Downregulates Heparanase and Pro-Angiogenic Growth Factors. (2007) (0)
CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma. (2023) (0)
Abstract C283: Non-malignant cells from tissues targeted by metastatic breast cancer induce tumor cell resistance to antiestrogens and conventional chemotherapeutic agents. (2013) (0)
Co-Expression Of The MUC1 Oncoprotein and CD34 On Primary Myeloma Bone Marrow Cells Identifies a Population With Myeloma Initiating Potential (2013) (0)
Methyljasmonate, An Inhibitor of Glycolytic Energy Production, Displays Pre-Clinical Activity against Multiple Myeloma Cells. (2009) (0)
Correction: Heat Shock Protein 90 Is Critical for Regulation of Phenotype and Functional Activity of Human T Lymphocytes and NK Cells (2013) (0)
Hsp90 Is Critical for the Regulation of Human T Lymphocytes and NK Cell Phenotype and Function. (2005) (0)
Mimicking Myeloma Niche Ex Vivo (2014) (0)
Novel Agents in Multiple Myeloma (2013) (0)
Modulation of heparanase expression in myeloma tumor cell lines by defibrotide: A novel mechanism of anti-tumor activity (2007) (0)
Temporal Dynamics of Tumor-Microenvironment Interaction and Treatment Responses Revealed through Time-Lapse Compartment-Specific Bioluminescence Imaging: Translational implications (2014) (0)
proteasome inhibitor PS-341 resistance in multiple Targeting mitochondria to overcome conventional and (2004) (0)
A novel panel of protein biomarkers for predicting response to thalidomide‐based therapy in newly diagnosed multiple myeloma patients (2011) (0)
Targeting the Ubiquitin-proteasome System in Multiple Myeloma: Examining the Roots of Success (2015) (0)
Procedes et compositions de traitement du cancer au moyen d'inhibiteurs de la proteasome (2003) (0)
beta-lapachone, a novel topoisomerase I inhibitor, has significant cytotoxicity against multiple myeloma (MM) cell lines and patient cells. (2001) (0)
Constitutive Vs. Stroma-Induced Kinase Dependencies in Myeloma Cells: Functional Mapping Using Small Molecule Inhibitors As Chemical Probes (2015) (0)
Abstract 667: Single-cell functional genomics of natural killer cell evasion by tumor cells (2023) (0)
Cells of the Osteoblast Lineage Confer Myeloma Cell Resistance to Established and Investigational Therapeutic Agents (2012) (0)
The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Induces Growth Arrest and Apoptosis in Human Retinoblastoma Cell Lines (2003) (0)
Increased TCF-4 Expression Correlates with Reduced Caspase-3 Induction and Confers Resistance to Bortezomib. (2004) (0)
In situ detection of microRNAs146b, 221 and 222 in human carcinoma tissues reveals tumor-type specific expression patterns. (2007) (0)
Association of tagging SNPs in genes related to IGF-1 or IL-6 signaling with risk of multiple myeloma : selected findings (2008) (0)
Proteasome inhibitors: beyond NFKB inhibition alone and the emerging role of combination therapy in the treatment of multiple myeloma (2009) (0)
CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias (2018) (0)
Effect of nonmalignant accessory cells from the metastatic microenvironment on breast cancer cell resistance to antiestrogens. (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Constantine S. Mitsiades?

Constantine S. Mitsiades is affiliated with the following schools:

Constantine S. Mitsiades's Academic­Influence.com Rankings

Why Is Constantine S. Mitsiades Influential?

Constantine S. Mitsiades's Published Works

Published Works

What Schools Are Affiliated With Constantine S. Mitsiades?

Constantine S. Mitsiades's AcademicInfluence.com Rankings